Regulation 13B Coronavirus and influenza vaccinations and immunisationsF1
No charge is payable under these Regulations in respect of the supply or administration to an eligible person of a medicinal product used for vaccination or immunisation against coronavirus or influenza virus.
In this regulation—
“coronavirus” has the meaning given in section 1(1) of the Coronavirus Act 2020; and
“eligible person” means a person who is of a class or description that means they would be entitled to be supplied with the medicinal product, or have it administered to them, in accordance with—
- (a)
a national patient group direction under regulation 233 of the Human Medicines Regulations 2012 (exemption for supply etc under a PGD by a person conducting a retail pharmacy business), signed on behalf of F2NHS England in accordance with paragraph (5)(a) of that regulation; or
- (b)
a national protocol under regulation 247A of the Human Medicines Regulations 2012 (protocols relating to coronavirus and influenza vaccinations and immunisations) approved by the Secretary of State,
- (a)
whether or not the medicinal product is supplied or administered to that person in accordance with such a patient group direction or protocol.
Annotations
Textual amendments
- F1
Reg. 13B inserted (9.11.2020) by The National Health Service (Charges and Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2020 (S.I. 2020/1126), regs. 1(2), 29
- F2
Words in Regulations substituted (6.11.2023) by The Health and Care Act 2022 (Further Consequential Amendments) (No. 2) Regulations 2023 (S.I. 2023/1071), reg. 1(1), Sch. para. 1